Changes in antipsychotic drug usage and factors affecting the use of typical drugs based on nationwide health insurance data in South Korea

Lee, Sang Uk; Ryu, Vin; Soh, Minah; Kim, Chul-Eung; Park, Subin; Roh, Sungwon; Oh, In‐Hwan; Lee, Hyeyoung; Choi, SungKu

doi:10.1136/bmjopen-2017-020280

Cited by 7 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Medical Aid beneficiaries showed a higher acute appendicitis rupture rate than did National Health Insurance beneficiaries [8]. Among patients with schizophrenia, Medical Aid beneficiaries were less likely to use atypical drugs, which were recommended as the first-line treatment for schizophrenia, than National Health Insurance beneficiaries [9]. Medical Aid patients were more likely to discontinue lung cancer treatment than were high-income patients [10].…”

Section: Discussionmentioning

confidence: 99%

Trends in life expectancy among medical aid beneficiaries and National Health Insurance beneficiaries in Korea between 2004 and 2017

2019

View full text Add to dashboard Cite

Background Medical Aid beneficiaries in Korea are more likely to have poor health status and to receive insufficient healthcare services, but their life expectancy has not been compared with that of National Health Insurance beneficiaries. Methods We used the National Health Information Database in Korea to obtain aggregate data on the numbers of population and deaths according to calendar year (2004 to 2017), sex, age group, and insurance eligibility (Medical Aid or National Health Insurance). Between 2004 and 2017, a summed total of 697,503,634 subjects (combining numbers of subjects for 14 years) and 3,536,778 deaths, including 22,417,216 Medical Aid beneficiaries and 499,604 associated deaths, were used to construct annual abridged life tables. Results In 2017, the life expectancy of Medical Aid beneficiaries was 70.9 years, while that of National Health Insurance beneficiaries was 83.7 years. Between 2004 and 2017, life expectancy for Medical Aid beneficiaries increased by 8.7 years in men and 6.1 years in women, while life expectancy for National Health Insurance beneficiaries increased by 5.2 years in men and 4.5 years in women. The life expectancy difference between National Health Insurance beneficiaries and Medical Aid beneficiaries was especially great among men across all study periods. The life expectancy difference was 15.8 years for men and 8.9 years for women in 2017. Conclusions The life expectancy of Medical Aid beneficiaries was shorter than that of National Health Insurance beneficiaries. The government should implement policies to deliver more adequate health care to Medical Aid beneficiaries. Electronic supplementary material The online version of this article (10.1186/s12889-019-7498-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Trends in life expectancy among medical aid beneficiaries and National Health Insurance beneficiaries in Korea between 2004 and 2017

2019

View full text Add to dashboard Cite

show abstract

“…It is difficult to determine how the different event severity and timing of events might affect the current analyses. Moreover, there are a mix of advanced or metastatic and early breast cancer studies included in present study, and patients with metastatic breast cancer may have been exposed to a greater number of prior treatments that may also induced cardiotoxicity such as radiotherapy or anthracycline chemotherapy [62–66], which might affect cardiovascular outcomes. Thus, all of these above confounding variables including basic medication history and adjuvant therapy could not be considered in the analysis.…”

Section: Discussionmentioning

confidence: 99%

Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis

Zhang²,

Shen

et al. 2019

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

BackgroundCardiovascular events (CVEs) was considered as one of the primary cause to reduce the quality of life in breast cancer patients with aromatase inhibitors (AIs) treatment, which has not been sufficiently addressed. The aim of this study was to assess the correlation between risk of CVEs and AIs in patients with breast cancer.MethodsIncluded studies were obtained from the databases of Embase, Pubmed, Cochrane Library, Clinical Trials.gov, and reference lists. The main outcome measures were overall incidence, odds ratios (ORs), and 95% confidence intervals (CIs). Furthermore, the association and the risk differences among different tumor types, AIs,ages,or treatment regimens were conducted. Fixed-effect or random-effect models were applied in the statistical analyses according to the heterogeneity. Our analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.ResultsSeventeen studies, which included 44,411 subjects, were included in our analyses. The overall incidence of CVEs in AIs group was 13.02% (95% CI: 8.15–20.17%) and almost all of the high-grade CVEs occurred in patients treated with AIs. The pooled ORs of CVEs was 0.9940 (95% CI: 0.8545–1.1562). Under sub-group analysis, the incidence of CVEs related to exemestane was higher than that of controls (OR = 1.1564, 95% CI: 1.0656–1.2549), but no statistical differences in risk of CVEs were found in other sub-group analysis. No evidence of publication bias was found for incidence of CVEs in our meta-analysis by a funnel plot.ConclusionsThese results suggest that patients with breast cancer treated with AIs do not have a significant risk of developing CVEs in comparison with the controls, and exemestane might not be considered as the alternative AI to the breast cancer patients from the perspective of CVEs. Further studies are recommended to investigate this association and the risk differences among different tumor types, AIs or treatment regimens.

show abstract

“…The increased use of riluzole in China can be explained by several factors. First, the increasing GDP per capita and decreasing drug price in China enabled more patients to afford the drug [41]. Secondly, with an enhanced understanding of ALS amongst the general public, an increasing number of patients realize that the progress of the disease can be partly controlled by riluzole and that the prognosis can be improved [42].…”

Section: Riluzole Usementioning

confidence: 99%

Trends in the clinical features of amyotrophic lateral sclerosis: A 14‐year Chinese cohort study

Chen

Tang

et al. 2021

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose: The aim was to determine the transitional patterns in the clinical characteristics, treatments and comorbidities in amyotrophic lateral sclerosis (ALS) patients over the past 14 years using data from a large clinical cohort in mainland China. Methods: Sporadic ALS patients who visited the Peking University Third Hospital from January 2005 to December 2018 were included in this study. The 14 years were divided into three periods, and changes in the baseline characteristics of the participants were analyzed at 5-year intervals. Results: In total, 3410 patients with sporadic ALS were recruited: 2181 were men and 1229 were women. The proportion of patients with bulbar-onset ALS increased from 13.0% in 2005-2009 to 19.5% in 2015-2018 (p < 0.001). The mean (standard deviation) age at onset increased from 49.5 (11.4) years in 2005-2009 to 53.0 (11.0) years in 2015-2018 (p < 0.001). ALS patients with diabetes or hypertension showed a delay in ALS onset, and the delay was even more apparent when the patients had both comorbidities. The proportion of riluzole users in 2015-2018 was approximately 2.5-fold of that in 2005-2009 (p < 0.001). Conclusions:In the context of a lack of clinical data on ALS in mainland China, this study evaluated a large cohort of patients diagnosed over a 14-year period. The age at onset and percentage of patients who used riluzole both increased over the study period.Additionally, it was found that patients with comorbidities such as diabetes and hypertension had a delayed age of ALS onset.

show abstract

Changes in antipsychotic drug usage and factors affecting the use of typical drugs based on nationwide health insurance data in South Korea

Cited by 7 publications

References 29 publications

Trends in life expectancy among medical aid beneficiaries and National Health Insurance beneficiaries in Korea between 2004 and 2017

Trends in life expectancy among medical aid beneficiaries and National Health Insurance beneficiaries in Korea between 2004 and 2017

Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis

Trends in the clinical features of amyotrophic lateral sclerosis: A 14‐year Chinese cohort study

Contact Info

Product

Resources

About